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Zanamivir is a potent and specific inhibitor of influenza A and B virus neuraminidase, that is now approved for the
treatment, and is currently under development for the prophylaxis of influenza. To assess the safety of this drug in
asthmatics, 13 subjects with mild/moderate asthma [forced expiratory volume in 1 sec (FEV1)70% predicted,
reversibility of FEV1 to salbutamol 15%, concentration of methacholine causing a drop of 20% in the FEV1
(PC20FEV1)8 mg ml71], were recruited to a double-blind, randomized, placebo controlled, two way cross-over
study. Subjects received 10 mg zanamivir as a dry powder (265 mg blisters via a Diskhaler1 Sovnn Plastics Ltd.,
Berkshire, U.K.), or a matching placebo, twice daily on day 1 and then four times daily from day 2 to day 14, in two
separate periods separated by a washout period of 7 days. PC20FEV1 to methacholine was determined pre-study, on
day 1 after the evening dose and on day 14 after the last dose of the study drug. FEV1 was measured pre-study and
at regular intervals on days 1 and 14. Laboratory safety tests were performed on days 1, 7 and 15. Morning and
evening peak expiratory flow rate (PEFR) and any adverse events were recorded in a diary card.
Eleven subjects completed the study. One was withdrawn due to non-compliance, and one due to an adverse
event that occurred during the placebo period. On day 1 the geometric mean PC20 for zanamivir was 36% lower
than for placebo [ratio to placebo 064, (90% CI 044, 093)] and on day 14 this was 33% lower with zanamivir
[ratio to placebo 067 (90% CI 038, 115)]. Both these confidence intervals were within the pre-defined interval of
‘no clinically significant eect’ of 025–4 (i.e. a change of two doubling doses of methacholine PC20FEV1 which was
considered clinically significant). The time weighted mean FEV1 was 015 l (54%) lower for zanamivir on day 1
compared to placebo (90% CI 003, 028; P=0050) and 001 l higher compared to placebo on day 14 (90%CI
7012, 010; P=0912). The day 1 changes were not associated with any significant symptoms or requirement for
rescue bronchodilator therapy. Furthermore there was no apparent treatment dierence over the 14 day dosing
period in FEV1 data (90% CI: 7011, 005, P=057). The mean morning PEFR was 4 l min71 less for zanamivir
than for placebo (90% CI: 711, 3) and mean evening PEFR was 9 l min71 less (90% CI: 724, 5). The study
treatments were well tolerated by the subjects with no clinically significant adverse events attributable to zanamivir
treatment. Zanamivir inhaled as a dry powder does not significantly aect the pulmonary function and airway
responsiveness of subjects with mild/moderate asthma and therefore its use in such patients subjects is not precluded.
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Influenza viruses are responsible for respiratory illness with
variable morbidity and mortality depending on the age and
health of the infected individual. Symptoms of fever, chills,
myalgia, headache, malaise, sore throat and cough, rapidly
follow infection. The management of influenza includes
preventive vaccination, treatment with antiviral agents and/
or symptomatic treatment. Antigenic variability of influen-
za viruses has limited the success of vaccination. Amanta-Received 19 April 1999 and accepted in revised form 9 October
1999.
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0954-6111/00/020166+08 $35?00/0dine and rimantadine are the only approved anti-influenza
agents, but their use is limited by adverse side-eects, lack
of activity against influenza B virus and the rapid
emergence after treatment of drug resistant strains of virus.
In addition, rimantadine has limited availability outside the
U.S.A.
Zanamivir (GG167, GR121167X) has received first
approvals for treatment and is in late stage clinical
development for the prophylaxis of influenza A and
influenza B virus infections. It is a selective inhibitor of
the viral neuraminidase (1), a potent inhibitor of influenza
A and B viruses in vitro (IC50 0003–012mM) (2) and is
ecacious against influenza A and B virus in ferret and
mouse models of infection (3,4). Zanamivir has shown no
cytotoxicity in vitro, (2) and was safe and well tolerated in
the rat and dog (5).# 2000 HARCOURT PUBLISHERS LTD
REPEATED INHALED DOSES OF ZANAMIVIR IN ASTHMA 167Zanamivir is ecacious in shortening the duration and
decreasing the severity of experimental infections in hu-
mans when given by the intranasal route (6,7) and inhaled
zanamivir is therapeutically active and well tolerated in
acute, uncomplicated naturally occurring human influenza
(8–11). In addition, zanamivir, as a intravenous, intranasal
or oral inhaled (nebulizer and dry powder) formulation,
was found to be well tolerated in healthy subjects (12). In a
subset of high risk patients, including those with respiratory
disorders, in large randomized, placebo controlled trials for
the treatment of influenza, zanamivir significantly reduced
the duration and severity of influenza symptoms compared
to placebo (10,11). In these high risk patients, as well as the
study population as a whole, zanamivir was well tolerated
with an adverse event profile equivalent to placebo (10,11).
To further confirm the ecacy and safety of zanamivir in
high risk patients an additional clinical study of zanamivir
is now underway in influenza virus infected asthmatic
patients.
Patients with respiratory diseases such as asthma, are
especially aected by the consequences of influenza virus
infection (13,14), and their underlying disease is often
exacerbated and extended. Therefore zanamivir could be
useful in these patients, but it is important that the drug
does not adversely aect the asthma. We therefore studied a
small group of subjects with mild to moderate asthma, to
evaluate the eect of inhaled zanamivir dry powder on
pulmonary function and airway responsiveness and to
assess the safety and tolerability of repeat dose dry powder
zanamivir in these subjects.
Materials and methods
REGULATORY AND ETHICAL
Approval for this study was received from The Medicines
Control Agency, London, U.K. and the East Berkshire
Research Ethics Committee. All subjects gave written,
informed consent before the study started.
STUDY SITE
The study was conducted at Chiltern International, Stoke
Poges, U.K. Subjects entered the Study Unit the evening
before the start of dosing period and remained ‘in house’
for 48 h. The subjects were then allowed to leave the Unit
and return for subsequent measurements.
STUDY DESIGN
This was a double-blind, placebo controlled, two period,
cross-over study. Subjects with mild or moderate asthma
were randomized into two groups to receive either
zanamivir or placebo for 14 days during each period,
separated by a wash-out period of 7 days.
Subjects with asthma who were free from significant
cardiac, hepatic, renal, neurological, gastrointestinal, hae-
matological or psychiatric disease were enrolled. Thediagnosis of asthma was based on a history of recurrent
wheezing, which the subjects family physician had diag-
nosed and treated as asthma for 2 or more years. In
addition, within the 5 days prior to the study the subjects
had a percentage predicted forced expiratory volume in 1
sec (FEV1)70%, an improvement in the FEV1 after
inhaled salbutamol of15%, and a PC20FEV1 tomethacho-
line (i.e. the concentration of methacholine producing a 20%
fall in the FEV1 from the post-saline value during the
methacholine challenge) of 8 mg ml71. No subject was on
long-acting 2-agonists, theophylline or oral corticosteroids.
Short-acting -agonists were avoided for at least 8 h prior to,
and until the completion of the pulmonary function and
bronchial reactivity tests pre-study, on day 1 and on day 14.
Inhaled corticosteroids (51000 g of beclomethasone or
equivalent) were allowed on a fixed regimen throughout the
study, taken at least 1 h before zanamivir.
All spirometric measurements throughout the study were
made on two Vitalograph Compact II1 electronic spirom-
eters (Vitalograph Ltd, Maids Moreton House, Maids
Moreton, Bucks, U.K.) which were calibrated daily. The
percent predicted values were based on the European
Community for Steel and Coal (ECSC) prediction equa-
tions (15), using an ethnic correction where appropriate
(16). The methacholine challenge test was done by the
dosimeter method (17), using a Mefar1 dosimeter (Mefar
s.r.l., Via dei Prati, 62-25073 Bovezzo, Italy). With the
method used a PC20FEV1 of 8 mg ml
71 was equivalent to a
PD20FEV1 (i.e. a provocating dose of methacholine causing
a 20% drop in FEV1) of 4 mol.
Subjects fasted for at least 12 h before laboratory safety
tests pre- and post-study and on days 1, 7, and 15.
Caeinated food and beverages were not allowed for 10 h
prior to the pulmonary function and methacholine chal-
lenge test pre-study and for 12 h before dosing on day 1 and
day 14. Alcohol was not allowed for 24 h prior to the tests
pre-study and on day 1 and for the duration of the study
period. Strenuous activity and physical exercise were
avoided for 24 h prior to dosing on days 1 and 14 and
was limited during the study (days 3–12). On day 1 and day
14 all subjects were required to abstain from smoking.
ADMINISTRATION OF ZANAMIVIR
Subjects were randomized to receive either zanamivir 10 mg
(two inhalations), as a dry powder, or matching placebo,
twice daily at 0 and 8 h (e.g. 08:00 and 16:00) on day 1 and
then four times daily at 0, 4, 8 and 12 h (e.g. 08 00, 12 00, 16
00 and 20 00 hours) from day 2 to day 14. Zanamivir was
supplied as a four place RotadiskTM (Lawson Mardon
Singen Verpacku¨gen, Singen/Hohenturel, Germany), each
blister containing approximately 25mg of a powder mix of
micronised zanamivir (5mg) and lactose (20mg). The
blisters were discharged using a Diskhaler TM device.
PHARMACODYNAMICS
FEV1 was measured pre-study (within 5 days of the start of
the study), before the first daily dose of zanamivir on days
168 L. M. R. CASS ET AL.1, 7 and 14; at intervals (i.e. 1, 3, 6, 9, 15, 30, 45 min, 1, 1.5,
2, 3, 4 h) after the first daily dose on days 1 and 14; and 24 h
after the first morning dose on day 14. Peak expiratory flow
rate (PEFR) was also recorded twice daily by the subject on
a diary card using a Wright peak flow meter1 (Clement
Clark International Ltd., Airmed House, Edinburgh Way,
Harlow Essex, U.K.). PC20FEV1 was determined pre-study,
on day 1 after the evening dose and on day 14 after the last
dose of the study drug.
The study had over 80% power for declaring no eect of
zanamivir on PC20 (equivalence between the zanamivir and
placebo treatment groups). This was based on a decision of
no eect if the 90% confidence interval for the ratio of
treatments was contained within (025,4). Equivalence was
clinically defined as a ratio between treatments of no more
than two doubling concentrations with respect to metha-
choline PC20.
SAFETY EVALUATIONS
A full laboratory screen was done pre-study and repeated on
days 1, 7 and 15. In addition to the twice daily PEFR
measurements, the subjects also recorded any significant
respiratory symptomsorother adverse events onadiary card.
All thesewerereviewedonday7,and if therewasanyclinically
significant abnormality, the study medication was stopped.
WITHDRAWAL CRITERIA
Subjects were withdrawn from the study if there were
clinically significant adverse eects of the study drug,
abnormal laboratory test results or intercurrent illness.
Subjects not wishing to continue with the study for any
reasons were withdrawn.
DATA ANALYSIS
The FEV1 value was taken to be the maximum of the values
recorded at any time point. Mean morning and evening
PEFR were calculated separately for each subject as the
mean value over the whole treatment period.
The primary endpoint was the concentration of metha-
choline producing a 20% fall of FEV1 from the post-saline
value (PC20) during the methacholine challenge.
PC20 values were calculated using linear interpolation
between the log concentrations enclosing a 20% reduction
from the post-saline value. Where patients had a reduction
of more than 20% with the first methacholine concentra-
tion, PC20 was calculated using linear interpolation between
post-saline and the first concentration on an untransformed
scale. Patients not reaching a 20% reduction in FEV1 by the
end of the challenge had their PC20 values taken to be the
maximum methacholine concentration recorded; patients
not completing the methacholine challenge had their PC20
taken to be the last concentration of methacholine
administered.
After log transformation PC20 was analysed using
analysis of variance allowing for eects due to subject,
period and treatment. The estimates of the ratio of PC20 forzanamivir to placebo on day 1 and day 14 were calculated
together with 90% confidence intervals.
FEV1 and mean morning and evening PEFR were
analysed, untransformed, using analysis of variance as
above. For FEV1 data, weighted mean values were
calculated for day 1, day 14 and for days 1–14. These were
derived by calculating the area under the response-time
curve calculated using the trapezoidal rule, and were
subsequently divided by the overall amount of time from
which the data was collected.
A test of sequence eect was carried out by repeating the
analyses on all subjects with data from both periods and
allowing for eects due to subject within sequence,
sequence, period and treatment. The sequence eect was
tested by comparing the sequence term to the subject within
sequence term.
Results
STUDY POPULATIONÐDEMOGRAPHIC
DETAILS
Thirteen subjects (nine male and four female) aged 19– 49
years (mean age 36 years) with weight 510–930 kg (mean
weight 714 kg) took part in the study. All were on inhaled
salbutamol as required for their asthma. Ten were on
inhaled beclomethasone, in a dose ranging from 200–800 g
daily. The concomitant medications taken by the subjects
for the treatment of their asthma are shown in Table 1. One
was also on beclomethasone nasal spray for allergic rhinitis.
Eleven subjects completed the study; one was withdrawn
for non compliance and another for an adverse event not
related to zanamivir.
One subject included in the study had only 14%
reversibility to 200 g salbutamol by Metered Dose Inhaler
but had 19% reversibility to nebulised salbutamol. Another
subject showed mild hyperchromic microcytic anaemia, and
another had mild iron deficiency anaemia which was
treated. High creatine phosphokinase (CPK) was also
observed in this latter subject.
The eleven subjects completing the study were each
exposed to a total of 54 doses of 10 mg zanamivir and 54
doses of placebo. These doses were administered as twice
daily doses on day 1 and four times daily doses on days 2–
14, inclusive.
PHARMACODYNAMIC RESULTS
On day 1 the geometric mean PC20 for zanamivir was 36%
lower than for placebo [ratio to placebo 064 with 90% CI
(044, 093)]. PC20s on day 14 were similar to day 1 with the
geometric mean for zanamivir being 33% lower than for
placebo [ratio to placebo 067 with 90% CI (038, 115)].
Both of these confidence intervals lie within the interval of
equivalence of (025, 4) where equivalence was clinically
defined as a ratio between treatments of no more than two
doubling concentrations with respect to methacholine PC20.
The results of this analyses are shown in Table 2.
TABLE 1. Concomitant medication for the treatment of asthma in the 11 subjects who completed the study
Subject Drug Dose Units Frequency Route
1 Becotide 200 g b.d. Inhaled
Salbutamol 200 g prn Inhaled
2 Salbutamol 200 g prn Inhaled
Becotide 200 g b.d. Inhaled
3 Ventolin 200 g prn Inhaled
Becotide 200 g b.d. Inhaled
4 Ventolin 200 g prn Inhaled
Beclazone 100 g b.d. Inhaled
5 Ventolin 200 g prn Inhaled
Becotide 200 ug b.d. Inhaled
Beconase Spray 1*2 Pus Intranasal
6 Ventolin 100–200 g prn Inhaled
Becotide 400 g b.d. Inhaled
7 Beclomethasone 100 g b.d. Inhaled
9 Ventolin 100–200 g prn Inhaled
10 Ventolin 200 g prn Inhaled
Becotide 200 g b.d. Inhaled
12 Becotide 400 g b.d. Inhaled
Ventolin 200 ug prn Inhaled
14 Ventolin 200 g prn Inhaled
Becotide 100 g b.d. Inhaled
Becotide(beco.d.isks) 200 g o.d. Inhaled
Vento.d.isks 400 g prn Inhaled
b.d.: twice daily; prm: as required; o.d.: once daily.
TABLE 2. Comparison of PC20 on day 1 and day 14 for placebo and zanamivir
Placebo Zanamivir
10mg
Day 1
Number of subjects 11 11
Unadjusted geometric mean (mg/ml) 047 047
Adjusted geometric mean (mg/ml)* 064 040
Ratio of zanamivir to placebo 064
90% CI 044, 093
P-value 0059
Day 14
Number of subjects 11 11
Unadjusted geometric mean (mg/ml) 065 045
Adjusted geometric mean (mg/ml)* 066 044
Ratio of zanamivir to placebo 067
90% CI 038, 115
P-value 0209
CI: confidence interval. *Least squares mean adjusted for design imbalance. Four methacholine challenges were performed on
day 2 instead of day 1, one on day 3 instead of day 1 and four on day 15 instead of day 14.
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time weighted mean FEV1 was 015 l lower for zanamivir
on day 1 compared to placebo (90% CI 003, 028;
P=0050) and 001L higher compared to placebo on day
14 (90% CI 7012, 010; P=0912). Although statistically
significant, the day 1 dierence was only 54% of the meanpost-dose FEV1, and was not associated with any
significant deterioration of asthma symptoms or require-
ment for rescue bronchodilators in any of the subjects.
Furthermore there was no apparent treatment dierence
over the 14 day dosing period in FEV1 data (90% CI
7011, 005, P=057). A listing of weighted mean data is
FIG. 1. Plot of mean forced expiratory volume in 1 sec
(FEV1) against time, (A), mean morning peak expiratory
flow rate (PEFR) against day (B) and mean evening
PEFR against day, (C); *—*: Placebo *—*
Zanamivir.
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statistical analysis are shown in Tables 4 and 5. A
discrepancy in the summary data from that of the statistical
analysis (Table 4) arises from the inclusion of the data from
subjects 8 and 11 who received only one treatment
(zanamivir and placebo, respectively) before withdrawal
from the study. Only one subject had a clinically significantdrop in FEV1, after inhalation of zanamivir, but not with
placebo, both on day 1 and day 14, but this rapidly
recovered spontaneously in about an hour.
Mean morning and evening PEFR were slightly lower for
zanamivir than for placebo, but these changes were not
clinically significant [Figs. 1(b) and (c), respectively]. Mean
morning PEFR was 4 l min71 less for zanamivir than for
placebo (90% CI: 11 l min71 less to 3 l min71 more), and
mean evening PEFR was 9 l min71 less (90% CI: 24 l
min71 less to 5 l min71 more). The results of this analysis
are shown in Table 6.
There was no evidence of a significant sequence eect.
ADVERSE EVENTS
There were no clinically significant abnormalities, no
serious adverse events nor clinically significant laboratory
abnormalities attributable to zanamivir treatment. Of the
129 adverse events reported during the study, most resolved
completely and those that remained were either related to
asthma or to allergic rhinitis. Only 37 events were
considered to be related to the study drug (Table 7), of
which 23 events occurred whilst subjects were on placebo.
LABORATORY SAFETY DATA
One subject receiving only placebo, was withdrawn from
the study following elevations in liver function tests, which
were probably related to gall stones. High creatine
phosphokinase (CPK) and mild/moderate eosinophilia
were observed randomly during the study, (pre-study, pre-
dose and/or on both study periods); the eosinophilia, which
also occurred pre-treatment, could have been related to the
asthma. The cause of the high CPK however, was often not
evident, but probably not related to the study drug. There
were no clinically significant abnormalities that were clearly
attributable to zanamivir treatment.
Discussion
The results of this study suggest that over a 14 day period,
orally inhaled dry powder zanamivir at twice the clinical
dose, was well tolerated in subjects with mild/moderate
asthma. Zanamivir did not have a clinically significant
eect on pulmonary function and airway responsiveness of
mild/moderate asthmatic subjects.
Airway responsiveness was assessed by a comparison of
the PC20 values recorded during the methacholine challenge
test on day 1 and day 14 and the data from the study
suggests that zanamivir may be considered to be clinically
equivalent to placebo in terms of the eect on airway
responsiveness.
Slight dierences in pulmonary function, as assessed on
day 1, 7 and day 14 by measuring FEV1 and daily morning
and evening PEFR, were observed between placebo and
zanamivir but again they were of no clinical significance.
The study findings indicate that zanamivir was well
tolerated and neither overtly exacerbated the medical
TABLE 3. Listing of weighted mean forced expiratory volume in 1 sec (FEV1) data for each subject
Subject Treatment Period Weighted
mean
days 1–14
Weighted
mean day 1
Weighted
mean day 14
1 Placebo 1 3368 3476 3455
Zanamivir 2 3147 3135 3209
2 Placebo 2 2115 2432 1948
Zanamivir 1 2201 2406 2168
3 Placebo 1 3241 3399 3260
Zanamivir 2 3101 3064 2882
4 Placebo 2 2613 2989 2922
Zanamivir 1 2756 2934 3187
5 Placebo 2 2729 2788 2771
Zanamivir 1 2829 2883 2919
6 Placebo 1 3186 3167 3293
Zanamivir 2 3323 3208 2995
7 Placebo 1 2446 2624 2487
Zanamivir 2 2376 2437 2578
8 Zanamivir 1 3465 3803
9 Placebo 1 3079 3230 3373
Zanamivir 2 3038 2793 2972
10 Placebo 2 2662 2843 2699
Zanamivir 1 3063 2821 3269
11 Placebo 1 1715 1893
12 Placebo 2 1839 1960 2187
Zanamivir 1 1815 2161 2184
14 Placebo 2 1974 2167 1877
Zanamivir 1 1980 1640 2235
TABLE 4. Summary statistics of weighted mean forced expiratory volume in 1 sec (FEV1) data
Day Treatment n Mean SD Median Minimum Maximum
Day 1 only Placebo 12 275 0542 282 189 348
Zanamivir 12 277 0557 285 164 380
Day 14 only Placebo 11 275 0571 277 188 346
Zanamivir 11 278 0421 292 217 327
Day 1–day 14 Placebo 12 258 0572 264 172 337
Zanamivir 12 276 0540 293 182 346
TABLE 5. Statistical analysis of weighted mean of forced expiratory volume in 1 sec (FEV1)
Day Comparison LSmean
Zanamivir
LSmean
Placebo
Treatment
dierence
90% CI P-value
Day 1 only Zanamivir—Placebo 268 284 015 (003, 028) 0050
Day 14 only Zanamivir—Placebo 277 276 7001 (7012, 010) 0912
Day 1–day 14 Zanamivir—Placebo 267 264 7003 (7011, 005) 0570
CI: confidence interval. LSmean: least squares mean. Least sqaures mean adjusted for design imbalance.
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TABLE 6. Comparison of mean morning and evening peak expiratory flow rate (PEFR) for placebo and zanamivir
Placebo Zanamivir 10mg
Mean morning PEFR
Number of subjects 12 12
Unadjusted geometric mean (l min71) 468 484
Adjusted geometric mean (l min71) 474 470
Dierence from placebo 74
90% CI 711, 3
P-value 0279
Mean evening PEFR
Number of subjects 12 12
Unadjusted geometric mean (l/min) 485 496
Adjusted geometric mean (l/min)* 494 484
Dierence from placebo 79
90% CI 724, 5
P-value 0264
CI: confidence interval. *Least squares mean adjusted for design imbalance.
TABLE 7. Adverse events related to study drug
Total number of events reported
(Number of subjects reporting events)
Zanamivir Placebo
Number of subjects 12 12
Total number of events 14 23
Number of subjects with any adverse event 6 7
Adverse Event
Chest symptoms (tight chest) 6(1) 4(4)
Malaise & fatigue — 1(1)
Headaches 3(3) 4(4)
Dizziness — 1(1)
Throat and tonsil discomfort — 1(1)
Chest sounds (wheezing) 2(1) 7(3)
Breathing disorders (increased breathlessness) 1(1) 3(1)
Lung function tests (low FEV1) — 1(1)
Nausea and vomiting 2(1) —
Abnormal liver function tests — 1(1)
172 L. M. R. CASS ET AL.condition of subjects with mild/moderate asthma, nor
interfered with other concomitant medications. Whilst this
study was performed in a selected population with a light
and well controlled disease, and not with influenza infected
airways, these observations suggest that the use of orally
inhaled dry powder zanamivir should not be precluded in
asthmatic patients.
Clinical studies have confirmed the safety and ecacy of
zanamivir in high risk patients including those with respira-
tory disorders (10,11). Further studies of zanamivir are now
underway in influenza virus infected asthmatic subjects.References
1. Von Itzstein M, Wu WY, Kok GB, et al. Rational
design of potent sialidase based inhibitors of influenza
virus replication. Nature 1993; 363: 418–423.
2. Woods JM, Bethell RC, Coates JAV, et al. 4-
Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneurami-
nic acid is a highly eective inhibitor both of the
sialadase (neuraminidase) and of growth of a wide
range of influenza A and B viruses in vitro. Antimicrob
Agents Chemother 1993; 37: 1473–1479.
REPEATED INHALED DOSES OF ZANAMIVIR IN ASTHMA 1733. Ryan D, Ticehurst J, Dempsey M, Penn CR. Inhibition
of influenza virus replication in mice by GG167 is
consistent with extracellular activity of viral neurami-
nidase (sialidase). Antimicrob Agents Chemother 1994;
38(10): 2270–2275.
4. Ryan D, Ticehurst J, Dempsey MH. GG167 (4-
guanidino-2,4-dideoxy-2,3-dehydro-n-acetylneuraminic
acid) is a potent inhibitor of influenza virus in ferrets.
Antimicrob Agents Chemother 1995; 39(11): 2583–2584.
5. Dines GD, Bethell R, Daniel M. Preclinical develop-
ment of low toxicity drugs; Focus on zanamivir, an
anti-influenza drug. Drug Safety 1998; 19(3): 233–241.
6. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart
JD, Hussey EK. Safety and ecacy of the neuramini-
dase inhibitor GG167 in experimental human influen-
za. JAMA 1996; 275(4): 295–299.
7. Walker JB, Hussey EK, Treanor JJ. Eects of
neuraminidase inhibitor zanamivir on otologic mani-
festations of experimental human influenza. J Infect Dis
1997; 176: 1417–1422.
8. Hayden FG, Osterhaus ADME, Treanor JJ, et al.
Ecacy and Safety of the neuraminidase inhibitor
zanamivir in the treatment of influenza virus infections.
New Eng J Med 1997; 337: 874–880.
9. Matsumoto K, Nerome K, Numasaki Y, et al. Inhaled
and intranasal GG167 in the treatment of influenza
A and B; preliminary results. Int Cngr Ser (1996),
1123. Options for the control of Influenza III;
713–717.
10. The MIST Study Group. Randomised trial of ecacy
and safety of inhaled zanamivir in treatment ofinfluenza A and B virus infections. Lancet 1998; 352:
1877–1881.
11. Monto AS, Fleming DM, Henry D, et al. Ecacy and
safety of the neuraminidase inhibitor zanamivir in the
treatment of influenza A and B virus infections. J Infect
Dis 1999; 180: 254–261.
12. Cass LMR, Efhymiopoulos C, Bye A. Review of the
pharmacokinetics of zanamivir after intravenous, oral,
inhaled or intranasal dosing in healthy volunteers.
Clinical Pharmacokinetics 1999, 36 (Suppl. 1): 1–11.
13. Nicholson KG, Kent J, Ireland DC. Respiratory
viruses and exacerbations of asthma in adults. B.
Med. J 1993; 307: 982–986.
14. Teichtahl H, Buckmaster N, Pertnikovs E. The
incidence of respiratory tract infection in adults
requiring hospitalisation for asthma. Chest 1997; 112:
591–596.
15. Quanjer PhH, Dalhuijsen A, Van Zomerren BC.
Summary equations of reference values. Bull Europ
Physiopathol Respir. 1983; 19 (suppl 5): 45–51.
16. Qunajer PhH, Tammelling GJ, Cotes JE, Pedersen OF,
Peslin R, Yernault J-C. Lung volumes and forced
ventilatory flows: Report working party, standardiza-
tion of lung function tests, European Community of
Steel and Coal: Ocial Statement of the Eurpean
Respiratory Society. Eur Respir J. 1993; 6 (suppl 16):
5–40.
17. Sterk PJ, Fabbri LM, Quanjer PhH, et al. Airway
Responsiveness: Standardized challenge testing with
pharmacological, physical and sensitizing stimuli in
adults. Eur Respir J. 1993; 6 (Suppl 16): 53–83.
